March 03, 2020
The Company received notification yesterday from Vulpes Life Sciences Fund ("Vulpes") that on 28 February 2020 it purchased 256,424 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.00p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,203,158 Ordinary Shares, equivalent to approximately 22 per cent of the issued share capital of the Company.